Evidence map›Paper›PMID 38542198›Full record

ArticleInternational journal of molecular sciences2024

Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on

Łukasz Uram, Natalia Pieńkowska, Maria Misiorek, Żaneta Szymaszek, Magdalena Twardowska, Michał Siorek, Stanisław Wołowiec

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Łukasz UramFaculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.ORCID 0000-0002-7964-0777
Natalia PieńkowskaDepartment of Experimental and Clinical Pharmacology, University of Rzeszów, Kopisto 2a, 35-959 Rzeszów, Poland.
Maria MisiorekFaculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Żaneta SzymaszekFaculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Magdalena TwardowskaFaculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Michał SiorekFaculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Stanisław WołowiecMedical College, University of Rzeszów, 1a Warzywna Street, 35-310 Rzeszów, Poland.ORCID 0000-0003-3215-9350
Rzeszów University of Technology · PLUniversity of Rzeszów · PL

Funding

National Science Centre, Poland 2014/13/D/NZ3/02825
6 · The paper itself

Abstract

Glioblastoma multiforme therapy remains a significant challenge since there is a lack of effective treatment for this cancer. As most of the examined gliomas express or overexpress cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptors γ (PPARγ), we decided to use these proteins as therapeutic targets. Toxicity, antiproliferative, proapoptotic, and antimigratory activity of COX-2 inhibitor (celecoxib-CXB) and/or PPARγ agonist (Fmoc-L-Leucine-FL) was examined in vitro on temozolomide resistant U-118 MG glioma cell line and comparatively on BJ normal fibroblasts and immortalized HaCaT keratinocytes. The in vivo activity of both agents was studied on

Indexed as

Caenorhabditis elegansGlioblastomaAnimalsApoptosisCelecoxibCell LineCell Line, TumorCyclooxygenase 2Cyclooxygenase 2 InhibitorsHumansLeucinePPAR gammaPyrazolesSulfonamidesTemozolomideCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsLeucine(N-(9-fluorenylmethoxycarbonyl)-)-L-leucinePPAR gammaPyrazolesSulfonamidesTemozolomideapoptosisATP levelcelecoxibC. elegansFmoc-L-Leucineglioma U-118 MGHaCaT immortalized cellsmigrationnormal human fibroblasts BJtoxicity

Identifiers

PMID38542198
PMCPMC10970558
OpenAlexW4392698854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.